Tissue Transglutaminase (TG2) as a Candidate Biomarker and Potential Therapeutic Target in Endometriosis: Functional Evidence from shRNA-Mediated Downregulation of TG2 in Endometrial Mesenchymal Stem Cells

Background/Objectives: Endometriosis involves the presence of endometrial tissue outside the uterus. Since the migration of endometrial cells is pivotal to lesion development, tissue transglutaminase (TG2)—known for its roles in cell adhesion, migration, and stemness—may play a significant role. This study aimed to investigate the involvement of TG2 in the migratory and invasive characteristics of endometrial mesenchymal stem cells (eMSCs) derived from healthy individuals and endometriosis patients. Methods: eMSCs were isolated from healthy controls (heMSCs) and endometriosis patients (peMSCs). TG2 protein expression and enzyme activity were evaluated. Co-immunoprecipitation (Co-IP) experiments were performed to assess TG2 associations with ITGβ-1 and SDC-4 in membrane fractions. Additionally, shRNA technology was utilized to silence TG2 in peMSCs to analyze its effects on cell proliferation, migration, invasion, and matrix metalloproteinase (MMP-2 and -9) activities. Results: peMSCs exhibited higher TG2 protein expression but lower enzyme activity compared to heMSCs. Co-IP analysis of membrane fractions revealed enhanced association of TG2 with ITGβ-1 and SDC-4 in peMSCs, thereby promoting enhanced cell survival, migration, and invasive properties. Silencing TG2 in peMSCs via shRNA eliminated these enhanced proliferation, migration, and invasion capabilities, reverting them to a phenotype resembling heMSCs. Furthermore, elevated MMP-2 and -9 activities returned to basal levels following TG2 knockdown. Conclusions: These findings suggest that TG2 acts as a distinctive cell adhesion molecule directly involved in endometriosis pathogenesis. Collectively, these findings identify TG2 as a disease-associated molecular marker warranting further evaluation for its diagnostic potential and suggest that targeting its cell-adhesion functions may represent a novel therapeutic strategy for endometriosis.

Authors

Institutions

Publication Details

Journal
Pharmaceuticals
Published
2026-09-25
DOI
https://doi.org/10.3390/ph19101520
Primary Topic
Blood properties and coagulation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Tissue Transglutaminase (TG2) as a Candidate Biomarker and Potential Therapeutic Target in Endometriosis: Functional Evidence from shRNA-Mediated Downregulation of TG2 in Endometrial Mesenchymal Stem Cells

Dilek Telci, Fikrettin Şahi̇n, Melike Batukan, İnci Kurt‐Celep
Pharmaceuticals
Blood properties and coagulation
article

Tissue Transglutaminase (TG2) as a Candidate Biomarker and Potential Therapeutic Target in Endometriosis: Functional Evidence from shRNA-Mediated Downregulation of TG2 in Endometrial Mesenchymal Stem Cells

Dilek Telci, Fikrettin Şahi̇n, Melike Batukan, İnci Kurt‐Celep
article en

Abstract

Background/Objectives: Endometriosis involves the presence of endometrial tissue outside the uterus. Since the migration of endometrial cells is pivotal to lesion development, tissue transglutaminase (TG2)—known for its roles in cell adhesion, migration, and stemness—may play a significant role. This study aimed to investigate the involvement of TG2 in the migratory and invasive characteristics of endometrial mesenchymal stem cells (eMSCs) derived from healthy individuals and endometriosis patients. Methods: eMSCs were isolated from healthy controls (heMSCs) and endometriosis patients (peMSCs). TG2 protein expression and enzyme activity were evaluated. Co-immunoprecipitation (Co-IP) experiments were performed to assess TG2 associations with ITGβ-1 and SDC-4 in membrane fractions. Additionally, shRNA technology was utilized to silence TG2 in peMSCs to analyze its effects on cell proliferation, migration, invasion, and matrix metalloproteinase (MMP-2 and -9) activities. Results: peMSCs exhibited higher TG2 protein expression but lower enzyme activity compared to heMSCs. Co-IP analysis of membrane fractions revealed enhanced association of TG2 with ITGβ-1 and SDC-4 in peMSCs, thereby promoting enhanced cell survival, migration, and invasive properties. Silencing TG2 in peMSCs via shRNA eliminated these enhanced proliferation, migration, and invasion capabilities, reverting them to a phenotype resembling heMSCs. Furthermore, elevated MMP-2 and -9 activities returned to basal levels following TG2 knockdown. Conclusions: These findings suggest that TG2 acts as a distinctive cell adhesion molecule directly involved in endometriosis pathogenesis. Collectively, these findings identify TG2 as a disease-associated molecular marker warranting further evaluation for its diagnostic potential and suggest that targeting its cell-adhesion functions may represent a novel therapeutic strategy for endometriosis.

PharmaceuticalsVol. 19(10)
Yeditepe University (TR), Okan University (TR)
Openalex Percentile: Top 12%
Blood properties and coagulation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.